SAN DIEGO, May 13, 2014 /PRNewswire/ -- OncoSec Medical
Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based
immunotherapy to treat solid tumors, announced today that it will
be a featured presenter at the 3rd Annual Marcum MicroCap
Conference on Thursday, May 29, 2014
in New York City at the Grand
Hyatt Hotel.
The Company's presentation by Punit
Dhillon, President and CEO, is scheduled to begin at
1:30 p.m. ET and will be available
via a live webcast. To access the webcast, go to
http://wsw.com/webcast/marcum2/oncs
The annual Marcum MicroCap Conference is a signature showcase
for superior quality, under-followed public companies with less
than $500 million in market
capitalization.
For more information or to register, please visit the conference
website at http://www.marcumllp.com/microcap or download the free
official conference app for the iPhone, iPad, or for Android mobile
devices in Apple's App Store and the Google Play Market.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response while minimizing the systemic
toxicities associated with other treatments. OncoSec's clinical
programs currently include three Phase 2 trials targeting
metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell
lymphoma
(http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination-based therapeutic approaches. For more information,
please visit www.oncosec.com.
About Marcum LLP
Marcum LLP is one of the largest independent public accounting
and advisory services firms in the United
States. Ranked #15 nationally, Marcum LLP offers the
resources of 1,300 professionals, including over 160 partners, in
23 offices throughout the U.S., Grand
Cayman and China.
Headquartered in New York City,
the Firm's presence runs deep, with full-service offices
strategically located in major business markets. Marcum is a member
of the Marcum Group, an organization providing a comprehensive
range of professional services spanning accounting and advisory,
technology solutions, wealth management, and executive and
professional recruiting. The Marcum Group companies include Marcum
LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial
Services LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan
Associates LLC; and Marcum Cronus Partners LLC. For more
information, visit www.marcumllp.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward-looking statements."
Forward-looking statements are based on management's current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
News Release
Investor Relations:
OncoSec Medical
Veronica Vallejo, CFO
855-662-6732
investors@oncosec.com
SOURCE OncoSec Medical Inc.